The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Meanwhile, investors await key clinical data.
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
But BeOne canned its alcestobart deal in May.
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
There are questions about vuso-vec’s supporting and confirmatory trials.
